Clin Colon Rectal Surg 2010; 23(3): 169-175
DOI: 10.1055/s-0030-1262984
© Thieme Medical Publishers

Enterocutaneous Fistula: Medical and Surgical Management Including Patients with Crohn's Disease

Guy R. Orangio1
  • 1Georgia Colon and Rectal Surgical Associates, P.C., Atlanta, Georgia
Further Information

Publication History

Publication Date:
24 August 2010 (online)

ABSTRACT

Patients with inflammatory bowel disease (IBD) and especially Crohn's disease can be challenging for even the most seasoned of surgeons. Development of an enterocutaneous fistula (ECF) in these patients further adds a level of complexity that requires a well-planned and defined management strategy. The role of the surgeon in caring for these patients should be as the leader of a multidisciplinary team, directing the care of the other specialists, all while determining if, and when, the patient requires operative intervention. Although medical management has come a long way in these and similar patients, surgery is still needed in a vast majority of patients. Therefore, understanding the evaluation, initial management, and important technical considerations for care of IBD and other complex patients with ECFs is a difficult, yet much needed, task for which the surgeon should be prepared.

REFERENCES

  • 1 Datta V, Engledow A, Chan S, Forbes A, Cohen C R, Windsor A. The management of enterocutaneous fistula in a regional unit in the United kingdom: a prospective study.  Dis Colon Rectum. 2010;  53(2) 192-199
  • 2 Berry S M, Fischer J E. Classification and pathophysiology of enterocutaneous fistulas.  Surg Clin North Am. 1996;  76(5) 1009-1018
  • 3 Mawdsley J E, Hollington P, Bassett P, Windsor A J, Forbes A, Gabe S M. An analysis of predictive factors for healing and mortality in patients with enterocutaneous fistulas.  Aliment Pharmacol Ther. 2008;  28(9) 1111-1121
  • 4 Heller L, Levin S L, Butler C E. Management of abdominal wound dehiscence using vacuum assisted closure in patients with compromised healing.  Am J Surg. 2006;  191(2) 165-172
  • 5 Khan J, Iiboshi Y, Cui L et al.. Alanyl-glutamine-supplemented parenteral nutrition increases luminal mucus gel and decreases permeability in the rat small intestine.  JPEN J Parenter Enteral Nutr. 1999;  23(1) 24-31
  • 6 Draus Jr J M, Huss S A, Harty N J, Cheadle W G, Larson G M. Enterocutaneous fistula: are treatments improving?.  Surgery. 2006;  140(4) 570-576, discussion 576–578
  • 7 Martinez J L, Luque-de-Leon E, Mier J, Blanco-Benavides R, Robledo F. Systematic management of postoperative enterocutaneous fistulas: factors related to outcomes.  World J Surg. 2008;  32(3) 436-443, discussion 444
  • 8 Visschers R G, Olde Damink S W, Winkens B, Soeters P B, van Gemert W G. Treatment strategies in 135 consecutive patients with enterocutaneous fistulas.  World J Surg. 2008;  32(3) 445-453
  • 9 Lynch A C, Delaney C P, Senagore A J, Connor J T, Remzi F H, Fazio V W. Clinical outcome and factors predictive of recurrence after enterocutaneous fistula surgery.  Ann Surg. 2004;  240(5) 825-831
  • 10 Bressler B, Sands B E. Review article: medical therapy for fistulizing Crohn's disease.  Aliment Pharmacol Ther. 2006;  24(9) 1283-1293
  • 11 Osterman M T, Lichtenstein G R. Infliximab in fistulizing Crohn's disease.  Gastroenterol Clin North Am. 2006;  35(4) 795-820
  • 12 Behm B W, Bickston S J. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.  Cochrane Database Syst Rev. 2008;  (1) CD006893
  • 13 Poritz L S, Rowe W A, Koltun W A. Remicade does not abolish the need for surgery in fistulizing Crohn's disease.  Dis Colon Rectum. 2002;  45(6) 771-775
  • 14 Ferrante M, D'Hoore A, Vermeire S et al.. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis.  Inflamm Bowel Dis. 2009;  15(7) 1062-1070
  • 15 Selvasekar C R, Cima R R, Larson D W et al.. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.  J Am Coll Surg. 2007;  204(5) 956-962, discussion 962–963
  • 16 Appau K A, Fazio V W, Shen B et al.. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients.  J Gastrointest Surg. 2008;  12(10) 1738-1744
  • 17 Goyer P, Alves A, Bretagnol F, Bouhnik Y, Valleur P, Panis Y. Impact of complex Crohn's disease on the outcome of laparoscopic ileocecal resection: a comparative clinical study in 124 patients.  Dis Colon Rectum. 2009;  52(2) 205-210

Guy R OrangioM.D. 

Georgia Colon and Rectal Surgical Associates

P.C., 5555 Peachtree Dunwoody Rd. NE, Ste. 206, Atlanta, GA 30342

Email: gorangio@comcast.net

    >